AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AMRN • US0231114044

14.75 USD
+0.66 (+4.68%)
Last: Feb 6, 2026, 08:17 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AMRN. AMRN was compared to 524 industry peers in the Biotechnology industry. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AMRN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • AMRN had negative earnings in the past year.
  • In the past year AMRN has reported a negative cash flow from operations.
  • In the past 5 years AMRN reported 4 times negative net income.
  • AMRN had negative operating cash flow in 4 of the past 5 years.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • AMRN has a Return On Assets of -13.12%. This is amongst the best in the industry. AMRN outperforms 81.68% of its industry peers.
  • Looking at the Return On Equity, with a value of -18.87%, AMRN belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

  • Looking at the Gross Margin, with a value of 54.96%, AMRN is in the better half of the industry, outperforming 77.10% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AMRN has declined.
  • The Profit Margin and Operating Margin are not available for AMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AMRN has been increased compared to 1 year ago.
  • The number of shares outstanding for AMRN has been increased compared to 5 years ago.
  • There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • AMRN has an Altman-Z score of -1.73. This is a bad value and indicates that AMRN is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.73, AMRN perfoms like the industry average, outperforming 53.63% of the companies in the same industry.
  • AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACC7.65%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.45 indicates that AMRN has no problem at all paying its short term obligations.
  • AMRN has a Current ratio of 3.45. This is comparable to the rest of the industry: AMRN outperforms 41.79% of its industry peers.
  • AMRN has a Quick Ratio of 2.43. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AMRN (2.43) is worse than 69.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 2.43
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.56%, which is quite impressive.
  • AMRN shows a decrease in Revenue. In the last year, the revenue decreased by -5.93%.
  • AMRN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.86% yearly.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%

3.2 Future

  • Based on estimates for the next years, AMRN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.76% on average per year.
  • AMRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.83% yearly.
EPS Next Y95.83%
EPS Next 2Y41.26%
EPS Next 3Y25.8%
EPS Next 5Y17.76%
Revenue Next Year6.41%
Revenue Next 2Y-6.99%
Revenue Next 3Y-5.16%
Revenue Next 5Y26.83%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AMRN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AMRN's earnings are expected to grow with 25.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.26%
EPS Next 3Y25.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMARIN CORP PLC -ADR

NASDAQ:AMRN (2/6/2026, 8:17:45 PM)

14.75

+0.66 (+4.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)03-10
Inst Owners20.09%
Inst Owner Change-27.5%
Ins Owners0.81%
Ins Owner Change0.11%
Market Cap306.69M
Revenue(TTM)226.73M
Net Income(TTM)-86.57M
Analysts42.86
Price Target12.24 (-17.02%)
Short Float %39.76%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)290.01%
Min EPS beat(2)113.76%
Max EPS beat(2)466.25%
EPS beat(4)3
Avg EPS beat(4)148.54%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)6
Avg EPS beat(8)97.31%
EPS beat(12)7
Avg EPS beat(12)68.9%
EPS beat(16)9
Avg EPS beat(16)50.01%
Revenue beat(2)2
Avg Revenue beat(2)22.82%
Min Revenue beat(2)12.99%
Max Revenue beat(2)32.65%
Revenue beat(4)3
Avg Revenue beat(4)24.22%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.46%
Revenue beat(12)9
Avg Revenue beat(12)12.72%
Revenue beat(16)10
Avg Revenue beat(16)8.28%
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)100%
EPS NY rev (1m)90.43%
EPS NY rev (3m)95.81%
Revenue NQ rev (1m)-7.54%
Revenue NQ rev (3m)19.58%
Revenue NY rev (1m)-3.29%
Revenue NY rev (3m)7.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS10.9
BVpS22.07
TBVpS21.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.96%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 2.43
Altman-Z -1.73
F-Score4
WACC7.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
EPS Next Y95.83%
EPS Next 2Y41.26%
EPS Next 3Y25.8%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%
Revenue Next Year6.41%
Revenue Next 2Y-6.99%
Revenue Next 3Y-5.16%
Revenue Next 5Y26.83%
EBIT growth 1Y34.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.77%
EBIT Next 3Y19.37%
EBIT Next 5YN/A
FCF growth 1Y-354.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-337.33%
OCF growth 3YN/A
OCF growth 5YN/A

AMARIN CORP PLC -ADR / AMRN FAQ

What is the fundamental rating for AMRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to AMRN.


What is the valuation status for AMRN stock?

ChartMill assigns a valuation rating of 1 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Overvalued.


Can you provide the profitability details for AMARIN CORP PLC -ADR?

AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AMARIN CORP PLC -ADR?

The Earnings per Share (EPS) of AMARIN CORP PLC -ADR (AMRN) is expected to grow by 95.83% in the next year.